The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.
about
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Rapid establishment of a HEK 293 cell line expressing FVIII-BDD using AAV site-specific integration plasmids.In vitro and In vivo Model Systems for Hemophilia A Gene Therapy.Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIIIAdvanced therapies for the treatment of hemophilia: future perspectives.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Advances in the treatment of inherited coagulation disorders.Production and purification of the multifunctional enzyme horseradish peroxidase.Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq(®) ) in children with severe haemophilia A: efficacy, safety and pharmacokinetics.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.Emerging drugs for the treatment of hemophilia A and B.Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.Production of recombinant coagulation factors: Are humans the best host cells?Synthetic mRNA is a more reliable tool for the delivery of DNA-targeting proteins into the cell nucleus than fusion with a protein transduction domain.Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.Efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.Simoctocog alfa for the treatment of hemophilia A.Prevention and Management of Bleeding Episodes in Children with Hemophilia
P2860
Q33841435-E68BA040-B2BB-45AD-B4D4-39EE84C14514Q34199436-A7AF62C5-669D-4770-80EF-1BDFCFBC9D03Q34499850-A0575774-7440-4271-BFE9-88D9DECD0BFDQ35779980-A4398C33-A561-4E20-9F98-04A4851F0FBAQ36294629-281D8D5A-F324-4F7D-B89A-E009A8E5D571Q36552555-97CE5EAF-4A13-4171-91CA-262E951A31C6Q37494846-1DF664E1-449D-46A4-8955-FC2C9AAC6AE2Q38100271-245D11BB-E0D2-49DE-839E-83E0D99A29B9Q38200605-F2A2C90A-0D76-463F-9F47-217B794A87CFQ38620816-08BCBADA-992F-4310-8C05-C4A2311C740FQ38705742-BB10DCAA-583A-4A88-8091-6CDC111A5A64Q38720560-FFE2F85E-F1D8-4177-AFC2-A5B5679ABA7DQ38722283-4F5430CE-4CAD-45A0-BF40-7DF75B884713Q38818573-4183AC20-5389-4C81-8024-31FCDE11BBB6Q38835294-92768CED-F41B-44A6-9BC6-32FDF7429D37Q38840145-E0540238-F05E-4901-9FCF-DE77B33E2A8DQ38933707-37FEA837-CB22-4E19-AD87-68D438850F43Q38996905-D735C683-D5EA-4DA7-8572-3F8A9137E199Q39170433-F2FA77C8-27DC-4BF2-8167-EA13C3522D4EQ41382102-AA3AA97E-4D39-46AD-9A90-EFD09683FA4BQ41639731-63EBB8E6-E62F-4AC1-A174-2BBB5E47CCF3Q45873356-C7E36B71-4DE2-46AA-9EC8-D906CC75CCBFQ45873366-B550731B-3FEE-43E7-A976-D7C9300F73AEQ58726516-D56FC052-39DE-485E-8EBF-F8E299D2246A
P2860
The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The first recombinant human co ...... manufacturing characteristics.
@ast
The first recombinant human co ...... manufacturing characteristics.
@en
type
label
The first recombinant human co ...... manufacturing characteristics.
@ast
The first recombinant human co ...... manufacturing characteristics.
@en
prefLabel
The first recombinant human co ...... manufacturing characteristics.
@ast
The first recombinant human co ...... manufacturing characteristics.
@en
P2093
P2860
P1476
The first recombinant human co ...... manufacturing characteristics.
@en
P2093
Carola Schröder
Elisabeth Casademunt
Kristina Martinelle
Lothar Biesert
Mats Jernberg
Maya Tiemeyer
Olaf Walter
Sigurd Knaub
Stefan Winge
P2860
P304
P356
10.1111/J.1600-0609.2012.01804.X
P577
2012-06-15T00:00:00Z